Indian Kanoon - Search engine for Indian Law

ChrysCapital currently holds less than or equal to 10 percent of Competition Appeal (AT) No. 01 of 2022 Competition Appeal (AT) No. 02 of 2022 Competition Appeal (AT) No. 03 of 2022 the share capital in each of Mankind Pharma Limited (Mankind) and Eris Lifesciences Limited (Eris); and less than 20 percent of the share capital in each of GVK Biosciences Private Limited (GVK) and Curatio Healthcare Private Limited (Curatio).

10. The interest of ChrysCapital in Eris is limited to its shareholding. Therefore, Eris has not been considered for identification of overlaps between the portfolio of ChrysCapital and Intas. However, its interest in GVK, Curatio and Mankind include board representation, right to seek information as well as the right to veto certain corporate actions including the change in capital structure, mergers and acquisitions, commencing new line of business and amendment to charter documents (GVK, Curatio and Mankind shall be together referred to as Portfolio Entities). A holistic appreciation of these rights suggest that ChrysCapital enjoys the ability to influence the strategic focus and operations of GVK, Mankind and Curatio. By way of the Proposed Combination, the Acquirers now propose to acquire minority shareholding in Intas along with rights to participate in some of its strategic corporate actions.